Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
114.23
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
February 29, 2024
SRPT earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sarepta Therapeutics: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
February 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Is It Too Late to Buy Sarepta Therapeutics Stock?
February 28, 2024
The company's hyperfocus on its core area could continue to be highly lucrative.
Via
The Motley Fool
A Preview Of Sarepta Therapeutics's Earnings
February 27, 2024
Via
Benzinga
In-Depth Examination Of 13 Analyst Recommendations For Sarepta Therapeutics
February 15, 2024
Via
Benzinga
Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts
January 30, 2024
Via
Benzinga
Earnings Scheduled For February 28, 2024
February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
Via
Benzinga
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
February 21, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 19, 2024
Via
Benzinga
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
February 16, 2024
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.
Via
Benzinga
Exposures
Product Safety
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 16, 2024
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.
Via
Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
February 16, 2024
The biotech just scored a big FDA win with an even bigger one potentially coming by June.
Via
The Motley Fool
Exposures
Product Safety
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
February 16, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 16, 2024
Via
Benzinga
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
February 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
2 Magnificent Growth Stocks to Buy With $500
February 15, 2024
No need to break the bank to invest in promising stocks.
Via
The Motley Fool
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
February 12, 2024
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.
Via
Benzinga
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
February 11, 2024
Bad news for one player does not always equal good news for another.
Via
The Motley Fool
Decoding Bearish Analog And The Warning Signs You Can't Ignore
February 07, 2024
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
February 06, 2024
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
February 06, 2024
PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy
Via
MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
January 29, 2024
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.
Via
Benzinga
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
January 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
MarketBeat Week in Review: 1/22 - 1/26
January 27, 2024
Markets continued to push to new all-time highs, setting the stage for big tech earnings, which will happen next week; here are the top stories from this week.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.